| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
SARS CoV-2 Spike Glycoprotein South Africa variant Blocking Peptide for STJ506305 is synthetically produced from the 400-450 sequence about the South Africa variant and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: |
400-450 |
| Specificity: |
This blocking peptide is recommended for use in combination with SARS CoV-2 Spike Glycoprotein South Africa variant antibody, STJ506305 |
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
